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Adult Celiac Disease and Its Malignant Complications 
Hugh J. Freeman
Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, Canada
Adult celiac disease is a chronic intestinal disorder that 
has been estimated to affect up to 1-2% of the pop-
ulation in some nations. Awareness of the disease has 
increased, but still it remains markedly underdiagnosed. 
Celiac disease is a pathologically defined condition with 
several characteristic clinical scenarios that should lead 
the clinician to suspect its presence. Critical to diag-
nosis is a documented responsiveness to a gluten-free 
diet. After diagnosis and treatment, symptoms and biop-
sy-proven changes may recur and appear refractory to 
a gluten-free diet. Recurrent symptoms are most often 
due to poor diet compliance, a ubiquitous and unrecog-
nized gluten source, an initially incorrect diagnosis, or 
an associated disease or complication of celiac disease. 
Some patients with persistent symptoms and biop-
sy-proven changes may not have celiac disease at all, 
instead suffering from a sprue-like intestinal disease, 
so-called unclassified sprue, which is a specific entity 
that does not appear to respond to a gluten-free diet. 
Some of these patients eventually prove to have an un-
derlying malignant cause, particularly lymphoma. The 
risk of developing lymphoma and other malignancies is 
increased in celiac disease, especially if initially diag-
nosed in the elderly, or late in the clinical course of the 
disease. However, recent studies suggest that the risk 
of gastric and colon cancer is low. This has led to the 
hypothesis that untreated celiac disease may be pro-
tective, possibly due to impaired absorption and more 
rapid excretion of fat or fat-soluble agents, including hy-
drocarbons and other putative cocarcinogens, which are 
implicated in the pathogenesis of colorectal cancer. (Gut 
and Liver 2009;3:237-246)
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INTRODUCTION
  Celiac disease has become increasingly recognized. In 
F in la n d , a  p re v a le n c e  o f u p  t o  2 %  h a s  b e e n  n o t e d  in  re-
cent decades.
1 In adults, the disorder often presents with 
chronic diarrhea, weight loss and malabsorption. Howev-
er, some have no diarrhea and weight loss is not evident. 
Instead, iron deficiency or alterations in blood chemistry 
values (e.g., low serum albumin) occur. Or, a closely- 
linked clinical disorder may be present (e.g., autoimmune 
thyroid disease, insulin-dependent diabetes, dermatitis 
herpetiformis). More recently, there has been an in-
creased recognition that some neurological disorders, 
such as dementia in the elderly, should even be con-
sidered.
2 Finally, positive screening blood tests (e.g., en-
domysial or tissue transglutaminase antibodies), though 
not diagnostic, may lead to suspicion of celiac disease.
DIAGNOSIS OF CLASSICAL CELIAC DISEASE
  Diagnosis of celiac disease rests on 2 specific, and se-
quential, criteria: first, typical biopsy changes need to be 
shown in proximal small intestine before treatment; and 
second, an unequivocal clinical and/or pathological re-
sponse must be documented in response to a gluten-free 
diet.
3 With a gluten-free diet, the diarrhea should resolve 
a n d  w e i g h t  g a i n  s h o u l d  o c c u r ,  a t  l e a s t  s u f f i c i e n t  t o  p r o -
vide a convincing clinical diagnosis. However, with lim-
ited symptoms, repeated biopsies may be needed to dem-
onstrate histological improvement. Recently, it has be-
c o m e  a p p r e c i a t e d  t h a t  o v e r  5 0 %  o f  c e l i a c s  m a y  n o w  b e  
classified as overweight or obese.
4 In these, weight gain 
has also been shown with a gluten-free diet.
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Fig. 1. Biopsy-proven changes of untreated celiac disease. Villi 
are “flattened” and rudimentary, while crypts are expanded and 
hyperplastic with increased numbers of epithelial cells and an 
increased mitotic index. The cellularity of the lamina propria is 
enhanced, and there is an increased number of plasma cells 
and lymphocytes (Adapted from Freeman HJ. Pearls and 
pitfalls in the diagnosis of adult celiac disease. Can J Gas-
troenterol 2008;22:273-280).
Fig. 2. High-magnification photograph of the field shown in 
Fig. 1 showing increased numbers of intraepithelial lympho-
cytes (Adapted from Freeman HJ. Pearls and pitfalls in the 
diagnosis of adult celiac disease. Can J Gastroenterol 2008; 
22:273-280).
Fig. 3. Biopsy specimen showing normalization of biopsy- 
proven changes following implementation of a gluten-free diet. 
The villi are elongated, the crypt shortened, and the cellularity
of the lamina propria is much reduced (Adapted from Freeman 
HJ. Pearls and pitfalls in the diagnosis of adult celiac disease.
Can J Gastroenterol 2008;22:273-280).
be solely relied upon for diagnosis.
5,6 Interestingly, the 
fate of different celiac antibodies in genetically at-risk 
children on a normal diet have been examined and shown 
to spontaneously disappear.
7 False negative serological 
tests also occur (e.g., concomitant IgA deficiency). So, if 
there is clinical suspicion of celiac disease in an adult, 
then a biopsy should be done. Clearly, a biopsy will be 
needed to determine if the serologically-based suspicion 
of celiac disease was correct since false-positive blood 
tests also occur. In a recent study, for instance, no biopsy 
evidence of celiac disease was present despite very high 
tissue transglutaminase values.
8
  Histopathological changes in classic celiac disease are 
typically present in the proximal rather than distal small 
bowel and have been classified elsewhere based on the 
degree of altered architecture.
3 Other different classi-
fication methods have been reported. For example, the 
Marsh classification
9 as modified by Oberhuber et al.
10 has 
found its way into the clinical realm, but a recent histo-
pathological evaluation concluded that this particular 
schema was cumbersome and intraobserver agreement 
was reduced.
11  
  Most often, a “severe (flat) mucosal lesion” is found 
(Figs. 1 and 2). This has also been labeled the “flat de-
structive” or “Marsh 3 lesion”. The villi are rudimentary. 
Lamina propria lymphoid cell elements are increased, par-
ticularly plasma cells and lymphocytes. Intraepithelial 
lymphocytes are also increased. The surface epithelium 
may appear more cuboidal (rather than columnar). Crypt 
epithelium is hyperplastic with increased numbers of cells 
and an increased mitotic index. Subcellular changes (e.g., 
increased epithelial vacuolization) occur and the glyco-
calyx is altered (i.e., shown with fluorescein-linked lec-
tins).
12 With a strict gluten-free diet, these histopatho-
logical changes revert to normal.
3 Comparable biopsy 
sites will eventually improve towards normal (Fig. 3), but 
these changes may require prolonged periods,
13 especially 
in older adults.
14
  In some, less severe architectural changes have been 
noted. In part, this may reflect increased use of sero-
logical detection methods. The villous architecture may be 
minimally altered and labeled a “mild lesion” (i.e., 
“infiltrative” or “Marsh 1 lesion”). However, epithelial 
cells show some loss of polarity and intraepithelial lym-
phocytes are increased.
3,9 In a “moderate lesion” (i.e., 
“infiltrative hyperplastic” or “Marsh 2 lesion”), definite 
changes in the architecture of the villus are visualized. 
Less severe changes may also occur in dermatitis herpeti-Freeman HJ: Adult Celiac Disease and Its Malignant Complications    239
formis and asymptomatic first-degree relatives.
3,9 If less 
severe changes are detected, however, studies to exclude 
other non-celiac causes, particularly infections (e.g., giar-
diasis, cryptosporidiosis) are critical. Epithelial lymphocy-
tosis alone with normal small bowel architecture may re-
spond to a gluten-free diet in about 10%, suggesting that, 
occasionally, an increased intraepithelial lymphocyte count 
alone may suggest celiac disease.
15 S o m e  h a v e  c l a i m e d  
that the celiac disease can be defined without quantitative 
changes in lymphocyte numbers using immunohistoche-
mical markers alone. However, these reported qualitative 
changes need to be confirmed.
16
  Pathological changes in celiac disease also occur along 
the length of the small bowel but may be poorly 
appreciated.
17 These may have particular importance in 
assessing the response to a gluten-free diet. The extent of 
these histological changes generally seems to correlate 
with the severity of the clinical presentation. In classical 
celiac disease with diarrhea and weight loss, severe patho-
logical changes may extend well into the jejunum. In the 
ileum, variably severe, often patchy, changes may also oc-
cur, but usually, ileal biopsies are normal. Some believe 
that this “proximal-to-distal” gradient in severity of 
pathological changes reflects higher concentrations of di-
etary gluten (or its derivative peptides) in the proximal 
small bowel. Alternatively, changes may be “indirect” due 
to immune-mediated effects driven by re-circulating mem-
ory T-cells.
18 Even though the ileum is often normal, pri-
or studies have shown that the ileum in celiac disease is 
very sensitive to gluten peptides infused through long in-
testinal tubes.
17 With extensive small intestinal involve-
ment, diarrhea and malabsorption of many nutrients may 
result. In contrast, deficits may be very limited if the ex-
tent of pathological change is limited (e.g., duodenum 
alone). In this setting, diarrhea and weight loss may not 
be evident. In some, only isolated iron deficiency may be 
present, in part, due to the major localization of celiac 
disease in the duodenum, the principal site for iron 
absorption.
  Treatment with a strict gluten-free diet normally should 
result in resolution of the diarrhea and significant weight 
gain. As the clinical state improves, biopsies normalize, 
initially in more distal sites of small bowel involvement, 
and later, in the proximal small bowel.
3 T o  v e r i f y  t h a t  a 
gluten-free diet biopsy response has occurred, however, 
prolonged periods of gluten restriction may be necessary, 
even months or years, before normal proximal duodenal 
mucosa can be defined.
13 Repeated endoscopic biopsies 
may sometimes be done, usually from duodenum. If nor-
malization of duodenal biopsies fails to occur within a 
few months, a potential clinical pitfall may result. The 
disease may be erroneously labeled “refractory”, even 
though a diet-induced response may have been initiated, 
but only in more distally involved small bowel.
19
OCCULT AND LATENT CELIAC DISEASE
  Celiac disease may be clinically occult and may not be 
detected even until late adult years.
20 In some with sub-
clinical disease, only isolated deficiencies of specific nu-
trients (i.e., iron, calcium) may develop without diarrhea 
or weight loss. Typical intestinal symptoms are absent or 
minimal and some have termed this presentation as 
“silent”. Some initially present with the skin disorder, 
dermatitis herpetiformis,
21,22 autoimmune thyroid dis-
ease,
23 insulin-dependent diabetes,
24 a small intestinal car-
cinoma
25 or lymphoma.
26 Occult celiac disease has also 
been associated with other intestinal disorders including: 
collagenous colitis,
27 lymphocytic colitis,
28 lymphocytic 
sclerosing cholangitis,
29 collagenous and lymphocytic gas-
tritis.
30
  Latent celiac disease is a separate form of subclinical 
disease initially reported in dermatitis herpetiformis,
31 
and later in small intestinal lymphoma.
32 In these reports, 
the small intestine was initially biopsy-normal. Then, 
pathological changes of variable severity were induced 
with a high-gluten diet showing that the mucosa was glu-
ten-sensitive (as volunteers fed high gluten diets do not 
develop histological changes). These gluten-induced chan-
ges also improved in both reports with a gluten-free diet.
ROLE OF ENDOSCOPY IN DIAGNOSIS
  The diagnosis of celiac disease is pathologically-based. 
Detection is optimized by submission of quality biopsies 
and close communication with an expert histopathologist. 
Endoscopic changes represent macroscopic changes only, 
are not specific and reflect the disappearance of normal 
mucosal patterns.
33-35 These cannot be relied upon for a 
precise diagnosis. A smooth tubular surface with loss of 
normal folds, “scalloped folds”, a mucosal “mosaic” pat-
tern with bulbar micronodularity are descriptive changes 
that are often used. “Scalloped folds”, however, have also 
been reported in Crohn’s disease with duodenal involve-
ment.
36 Similar macroscopic changes have been reported 
with emerging methodologies including capsule and dou-
ble-balloon enteroscopy. These mucosal changes that oc-
cur with direct visualization, however, may be limited and 
their correlation with microscopic alterations is limited. 
Conversely, and most important, a “normal” endoscopic 
appearance is not sufficient to exclude celiac disease. 
Experienced endoscopists, for example, estimated that 240   Gut and Liver, Vol. 3, No. 4, December 2009
Table 1. Causes of a Severe “Flat” or Variably Severe Biopsy Lesion*
Disease Treatment
Sprue syndromes
  Celiac disease (gluten sensitive enteropathy, celiac sprue) Gluten-free diet 
   Includes classic, occult and latent celiac disease
  Refractory sprue (or refractory celiac disease) Temporary response to gluten-free diet
  Collagenous sprue Unknown
  M e s e n t e r i c  l y m p h  n o d e  c a v i t a t i o n  s y n d r o m e U n k n o w n
  Other protein injury (soy protein, milk, oats, other proteins) Removal of specific protein 
  Unclassified sprue (or “sprue-like” intestinal disease) No response to gluten-free diet
Infectious causes
  Infectious gastroenteritis (usually in childhood) Spontaneous resolution
  Infections (parasites, viral, fungal, mycobacterial) Treat infection
  Tropical sprue  Antibiotics and folic acid
  Stasis syndrome (contaminated small bowel syndrome) Antibiotics
  Whipple’s disease (Tropheryma whipplei) Antibiotics
Deficiency syndromes
  Nutrient deficiency syndromes  Replace specific nutrient
   Includes zinc, vitamin B12, folic acid deficiencies
  Kwashiorkor Adequate dietary protein
  Immunodeficiency syndromes Not known
   Includes common variable immunodeficiency, AIDS
  Intestinal lymphangiectasia
Others
  Crohn’s disease Not known
  Graft-versus-host disease Graft rejection therapy
  Immunoproliferative diseases (e.g., lymphoma, T- or B-cell types) Often chemotherapy
  Macroglobulinemia or amyloidosis Often chemotherapy
  Zollinger-Ellison syndrome (with acid hypersecretion) Antisecretory therapy
*Modified from Freeman HJ. Small intestinal mucosal biopsy for investigation of diarrhea and malabsorption in adults. Gastrointest 
Endosc Clin N Am 2000;10:739-53, vii.
about 10% of their celiacs were only recognized because 
random biopsies from the duodenum were taken, not be-
cause endoscopic abnormalities were visualized.
37
OTHER CAUSES OF SEVERE (“FLAT”) OR VA-
RIABLY SEVERE LESIONS
  Other causes of severe or variably severe small bowel 
biopsy changes may be associated with diarrhea or mal-
absorption (Table 1). But, only celiac disease responds to 
a strict gluten-free diet. Oats may be safely consumed, 
but also can be contaminated by other grains.
38 In addi-
tion, oats alone has been reported to induce abnormal-
ities in villous architecture.
39
  Infections can produce a spectrum of histopathological 
changes, appearing like classical celiac disease. However, 
these changes are usually temporary and generally re-
spond to antibiotic treatment. These may occur in adults, 
but less often than in children. These may be due to an 
undetected viral agent or a bacterial infection that sponta-
neously resolved without treatment.
40 In adults, architec-
tural disturbance may be quite severe, but is usually 
variable. In giardiasis, for example, a common protozoan 
pathogen, up to 15% may have changes that are so archi-
tecturally abnormal as to mimic celiac disease (at least, 
until the organisms are detected in fecal material, luminal 
aspirates or the biopsy specimen). Other protozoans 
should also be excluded and include: Isospora belli, Crypto-
spordium parvum, Cyclospora cayetanensis and other micro-
sporidians such as Enterocytozoon bieneusi. Acquired im-
mune deficiency states that follow transplantation or HIV 
(retroviral) infection may also be associated with severe 
biopsy changes.
41 In the latter setting, the precise cause 
of pathologic changes may be difficult to determine be-
cause multiple infectious agents may be present. The ret-
roviral agent per se m a y  b e  d i r e c t l y  r e s p o n s i b l e ,  o r  a l t e r -
natively, indirectly due to the immunologic dysfunction, 
superimposed malnutrition or another infectious orga-
nism.  Mycobacterium avium-intracellulare infection, often 
seen with AIDS, is quite distinctive with lamina propria 
foamy macrophages that stain positive for acid-fast 
organisms.
42 These are also periodic acid-schiff positive 
reminiscent of Whipple’s disease, but with Trophyrema 
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Table 2. Causes of Refractory or Recurrent Disease*
1. Poor compliance to a gluten-free diet (i.e., most common cause, intentional or unrecognized)
2. Ubiquitous source of ingested gluten (e.g., pill capsules, communion wafers)
3. Superimposed cause (e.g., folic acid deficiency, zinc deficiency)
4. Second cause for symptoms (e.g., associated pancreatic exocrine insufficiency, superimposed infectious diarrhea)
5. Wrong initial diagnosis (e.g., Crohn’s disease of the duodenum, “sprue-like” intestinal disease or unclassified sprue*)
6. Associated or complicating clinical disorder (e.g., collagenous colitis, lymphoma)
*Failure to initially respond to a gluten-free diet suggests “sprue-like” intestinal disease or unclassified sprue, not refractory celiac 
disease.
negative. Parasites can also cause severe biopsy changes, 
but many can be morphologically identified in the biopsy 
material (e.g., Strongyloides stercoralis, hookworm, 
Schistosoma or Capillaria species). Some viral agents 
(e.g., cytomegalovirus) may be seen in the small bowel, 
often in the setting of an immune compromised state.
43
  Other disorders may cause diarrhea and/or malabsorp-
tion with severe biopsy changes like celiac disease. In 
some, distinct features are evident: lymphangiectasia, 
macroglobulinemia, amyloidosis, abetalipo-proteinemia, li-
pid storage disorders, radiation injury, and drugs (e.g., 
neomycin, busulfan, methotrexate, sulindac, azathio-
prine).
44 Although Crohn’s disease may cause mucosal 
granulomas in the duodenum,
45 severe architectural chan-
ges without granulomas similar to untreated celiac dis-
ease may occur in the proximal small intestine.
46 In 
Crohn’s disease, however, these pathological findings do 
not improve with a gluten-free diet.
REFRACTORY DISEASE AND SPRUE-LIKE IN-
TESTINAL DISEASE
  In celiac disease, diarrhea or malabsorption may recur. 
Even though the mucosa may normalize with gluten re-
striction, severe pathologic changes may then later 
recur.
19 A list of specific entities should be considered by 
the clinician (Table 2). Most often, symptoms and re-
current biopsy changes are due to poor compliance to the 
gluten-free diet; sometimes, this is completely inadvertent 
since gluten is ubiquitous and may be found in various 
ingested items, such as pill capsules or communion 
wafers. There may also be a difference in tolerance to glu-
ten with a minimum threshold in some groups. A super-
imposed cause (e.g., infection) or superimposed deficiency 
of one or more nutrients (e.g., folic acid, zinc) may be 
critical in causing independent histological changes that 
are difficult to differentiate from changes of celiac disease. 
In long-standing celiac disease, pancreatic exocrine in-
sufficiency may also occur, especially if concomitant mal-
nutrition is evident.
13 In some, it is also possible that the 
original diagnosis was not correct and some other cause 
for the severe biopsy changes was present. Finally, anoth-
er related disorder (e.g., collagenous colitis) or a partic-
ularly sinister complication (e.g., lymphoma) may cause 
recurrent symptoms.
  Rarely, an uncommon disorder, collagenous sprue, may 
complicate adult celiac disease.
47 Sometimes, it may be 
appear during the investigation of malabsorption or a di-
arrhea disorder, without any evidence of pre-existent cel-
iac disease. Panmalabsorption with diarrhea, weight loss, 
electrolyte abnormalities and marked nutritional dis-
turbance may be seen. Small bowel biopsies reveal a 
pathologically distinctive sub-epithelial band of collagen. 
Long term nutritional support with parenteral nutrition 
may be needed for survival. Antibodies to endomysium in 
collagenous sprue may reflect an immunological link to 
celiac disease.
48 Rarely, lymphoma may supervene in col-
lagenous sprue.
49,50 Occasionally, another distinctive syn-
drome may complicate celiac disease with recurrent small 
bowel changes of variable severity, splenic hypofunction, 
and mesenteric lymph node cavitation.
51 I n  t h is  d is o r d e r , 
lymphoma has also been recorded.
52
  Sprue-like intestinal disease (or unclassified sprue) re-
fers to a severe (“flat”) or variably severe (moderate to 
mild) mucosal lesion that has never responded to a glu-
ten-free diet.
19 Although some have labeled this entity as 
“refractory celiac disease”, response to a gluten-free diet 
has not been shown and so cannot be truly labeled with 
“celiac disease”. Usually, additional biopsies are abnormal 
despite a gluten-free diet. Most remain symptomatic and 
fail to clinically respond to a gluten-free diet. In some di-
etary compliance may be difficult to prove and histo-
logical improvement may be difficult to document, espe-
cially with duodenal biopsies alone. This group likely rep-
resents a heterogeneous collection of small bowel dis-
orders, a “wastebasket group” with no defined cause. 
Some may have a “resistant form” of celiac disease, while 
others prove to have a “difficult-to-diagnose” lymphoma. 
In some, an abnormal subset of intraepithelial lympho-
cytes with morphologically normal, but phenotypically ab-242   Gut and Liver, Vol. 3, No. 4, December 2009
normal lymphocytes was reported. These intriguing find-
ings could provide a prognostic marker for later lympho-
ma development but added confirmatory studies are 
needed.
INTESTINAL MALIGNANCIES AND RISK IN CE-
LIAC DISEASE
  Intestinal malignancies occur during the clinical course 
of adult celiac disease.
53-56 Often, these are lymphomas 
that complicate already well established celiac disease. 
But, in some, lymphoma as well as other malignancies, 
such as small bowel adenocarcinoma, actually precede rec-
ognition of celiac disease,
25,26 providing further evidence 
for an intimate clinical linkage.
  The precise risk of malignancy, particularly lymphoma, 
in adult celiac disease has been difficult to determine be-
cause there are many confounding variables. In adults 
with severe biopsy changes in proximal small intestine, 
the overall lymphoma risk was about 8 to 10% in a ter-
tiary care setting.
55,57 Age at the time of the initial diag-
nosis of celiac disease seems to be a critical risk factor. If 
celiac disease was first diagnosed later in life, lymphoma 
was detected more often than if the diagnosis of celiac 
disease was defined earlier. Duration on the gluten-free 
diet may be important. Interestingly, a long-term cohort 
study of 285 children with celiac disease treated with a 
gluten-free diet described only a single small bowel 
lymphoma.
58 Recent reports have also suggested that this 
excess lymphoma risk in celiac disease has actually de-
creased, related possibly to use of serological screening 
tests for celiac disease in those with limited symp-
toms.
59,60 
LYMPHOMA DIAGNOSIS IN CELIAC DISEASE
  The diagnosis of lymphoma in celiac disease may be 
challenging and sometimes presentations may be dramatic 
because most lymphomas in celiac disease occur in small 
intestine. Usually, these occur in jejunum, but localization 
in the ileum, also occurs.
54 Duodenal lymphoma may de-
velop while associated gastric and colonic lymphomas 
have been reported.
54 Ulcerating or stenosing and ob-
structing tumors are often seen.
61 Occasionally, however, 
the lymphoma may be multifocal or diffuse with only mu-
cosal localization. Concomitant nodal involvement may be 
present.
54 In some, a definite pathological diagnosis of 
lymphoma may be particularly difficult in the presence of 
either small intestinal (including duodenal) erosions or 
ulcers.
26 Crohn’s ulceration or a label of “ulcerative jeju-
noileitis” may be recorded.
26 Some of these ulcerating le-
sions, however, later prove to contain frankly neoplastic 
lymphoma cells that may be difficult to appreciate in se-
verely inflamed small intestine. Free perforation of the 
small intestine may be due to lymphoma, especially if cel-
iac disease is known to be present or suspected.
61 Even if 
there is a high degree of suspicion, lymphoma may still 
be notoriously difficult to diagnose, despite multiple en-
doscopic “pinch” or suction small intestinal biopsies.
52 In 
some that eventually prove to have a lymphoma, full 
thickness small intestinal biopsies may not have provided 
a definitive pathological diagnosis, especially if only focal 
mucosal lymphomatous involvement was present. In re-
cent years, tissue evaluated by flow cytometry and im-
munohistochemical studies or PCR have been added to 
the armamentarium of tools to facilitate diagnosis.
62
LYMPHOMA TYPES IN CELIAC DISEASE
    Lymphomas may be classified based on pathological 
and immunophenotypical features. Both B-cell and T-cell 
lymphomas occur in celiac disease. However, detection of 
a T-cell type more often leads to clinical suspicion of pos-
sible adult celiac disease. Primary intestinal T-cell lym-
phoma is recognized under the WHO classification sys-
tem as enteropathy-associated T-cell lymphoma (ETL or 
EATL). They are very uncommon and represent an esti-
mated 5% of all gastrointestinal lymphomas.
62,63 Indeed, 
in a recent population-based study from the Netherlands, 
the disease was most common in the proximal small in-
testine, usually defined by surgical resection, more preva-
lent in males than females and rare with a reported in-
cidence of 0.1 per 100,000 inhabitants per year.
64 Previo-
usly, these lymphomas were thought to be histiocytic in 
origin (and labeled malignant histiocytosis), but their ori-
gin now appears to be primarily from T-cells, particularly 
intraepithelial lymphocytes.
62,63 I n  c e l i a c  d i s e a s e  ( w i t h o u t  
lymphoma), intraepithelial lymphocytes express the fol-
lowing antigens (among others): CD3 surface ＋ and CD 
8＋. In a subset of patients that seem clinically refractory 
to a gluten-free diet, intraepithelial lymphocytes have a 
different form of T-cell phenotypic expression: CD 3 
shows intracytoplasmic (i.e., not surface) expression 
while CD 8 expression may be absent. Some studies have 
suggested that this may reflect a specific form of re-
fractory disease (type 2) with a poor prognosis and a pos-
sible precursor lesion for development of lymphoma.
65-68 
Defective synthesis of the T-cell receptor chains appears 
to be responsible for the loss of surface T-cell expres-
sion.
69
  Intestinal T-cell lymphomas are also a heterogeneous 
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of the intestine may occur that appears to have a distinct 
immunophenotype. This entity is not known to be asso-
ciated with celiac disease, progresses rapidly and has a 
poor prognosis.
70,71 Also, cases with both B-cell and T-cell 
type lymphomas have been described in the single in-
dividuals with celiac disease.
72,73
    Even lymphomas with T-cell immunophenotypic fea-
tures have been defined in extra-intestinal sites compli-
cating celiac disease but without lymphomatous intestinal 
involvement. These are rare and include hepatosplenic 
type T-cell lymphoma
74 or lymphoma occurring in other 
embryologically-related or gut-derived sites, including the 
thyroid gland
75 or bronchopulmonary and pleural sites.
  Recent studies also provide evidence for an increased 
risk for other lymphoma types. In a pathological review of 
tumor materials from celiacs, there was an apparent ag-
gregation of autoimmune and inflammatory disorders, fe-
male sex and B-cell lymphoma.
76 More than double the 
risk for B-cell lymphoma was recorded with the most 
common type classified as a diffuse large B-cell lym-
phoma. In the same study, T-cell lymphomas had an ap-
proximate 50-fold risk along with a poorer prognosis 
(reflected in mean survival time after diagnosis and 5-year 
survival rate.
76
LYMPHOMA TREATMENT
  Lymphoma treatment in celiac disease does not sub-
stantially differ from lymphoma treatment in the absence 
of celiac disease. Usually, surgery, radiation and chemo-
therapy have been used. Most believe that treatment re-
sults are best in those with an early diagnosis.
77 Novel 
treatments, such as cladribine, a purine analogue that in-
duces T-cell depletion,
78 and alemtuzumab, a biological 
agent,
79 along with autologous stem cell transplantation
80 
are being considered and evaluated.
  Newly diagnosed lymphoma patients should be scre-
ened for celiac disease, especially if chronic diarrhea or 
weight loss are evident. A diagnosis of celiac disease is 
more readily established prior to lymphoma treatment 
(since chemotherapy or radiation may induce small in-
testinal changes). Concomitant recognition of underlying 
celiac disease may also have important nutritional impli-
cations.
OTHER CANCERS
  Malignant disorders may occur elsewhere in the gastro-
intestinal tract in celiac disease. For some of these, the 
rate may be increased. Small bowel adenocarcinoma is 
normally rare, but may be more frequently recognized in 
celiac disease. Some have suggested that these may be 
due to an adenoma-carcinoma sequence,
54 but others have 
reported that the risk of duodenal adenoma is not in-
creased in celiac disease.
81 Most occur in the proximal 
small intestine and may cause bleeding or obstruction. If 
complete resection can be accomplished, the prognosis is 
better than if a lymphoma were present.
82
  Some European studies have also noted an increased 
risk of esophageal and pharyngeal carcinoma.
53,83 This has 
not been confirmed in American centers, but in one re-
port,
57 a single hypopharyngeal squamous cell carcinoma 
was detected in a celiac patient with a prior lymphoma. 
In the same series, other esophageal or gastric cancers 
were not detected, in spite of repeated endoscopic studies 
during the course of diagnosis and treatment of celiac 
disease, but Barrett’s esophagus, a known precursor of 
esophageal adenocarcinoma, was reported.
57 Possibly, en-
vironmental or other confounding factors in different geo-
graphic areas are responsible. 
  Colorectal cancer risk was marginally increased, mainly 
in the ascending and transverse colon,
84 in a pop-
ulation-based celiac cohort, but not in the closely allied 
disorder, dermatitis herpetiformis.
84 Other studies have 
not detected an increased colorectal cancer risk in celiac 
disease,
55,57,85 especially in celiac disease with a diagnosis 
initially established late in life.
55,57 Possibly, untreated cel-
iac disease protects from colon cancer. Dietary fat or fat 
soluble agents, including hydrocarbons or other putative 
co-carcinogens that have been implicated in colon cancer 
pathogenesis, may be poorly absorbed and rapidly ex-
creted. Alternatively, immunological changes (e.g., increa-
sed intraepithelial lymphocytosis) may prohibit develop-
ment of epithelial malignancies. Further studies to eluci-
date this issue are needed.
FUTURE DIRECTIONS
  Mechanisms involved in the development of malignancy 
in celiac disease are poorly understood, including both 
lymphoma as well as epithelial malignancies. The small 
intestinal mucosa involved with changes attributed to cel-
iac disease may still show histological improvement with 
a gluten-free diet, even after intestinal lymphoma is 
detected.
26,32 There are many potential confounding varia-
bles that may alter the pathogenesis of lymphoma in a 
celiac population and influence risk measurements in dif-
ferent countries. These include genetic, infectious (e.g., 
EB virus) and other dietary and epidemiological variables. 
Duration of gluten restriction and degree of compliance 
to a gluten-free diet are be specific factors that are diffi-
cult to measure precisely, but seem critical to malignant 244   Gut and Liver, Vol. 3, No. 4, December 2009
change in celiac disease. Other malignancies, particularly 
epithelial malignancies, such as gastric or colon cancer, 
seem to occur much less often, even if celiac disease is 
only first recognized later in life. Possibly, untreated cel-
iac disease protects against other cancers, such as colon 
cancer. Dietary fat or fat-soluble agents, such as hydro-
carbons or other putative co-carcinogens, implicated in 
colon carcinogenesis may be poorly absorbed or rapidly 
excreted in celiac disease with diarrhea and impaired 
absorption. Immunological alterations, associated with in-
creased intraepithelial lymphocyte numbers in celiac dis-
ease and the epithelial lymphocytosis reported in the 
stomach or colon of celiac,
28,29 may directly or indirectly 
inhibit development of epithelial malignancies, partic-
ularly at these sites. Further studies are needed to eluci-
date these observations in adults with celiac disease.
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